141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study

N. Reinmuth,J.W. Goldman,M.C. Garassino,Y. Chen, K. Hotta,A. Poltoratskiy,D. Trukhin, M.J. Hochmair, J.H. Ji,M. Özgüroğlu, G. Statsenko, O. Voitko,N.V. Conev,I. Bondarenko,H. Mann,M. Xie, Y. Shrestha, P. Chugh, T. Dalvi,L. Paz-Ares

Annals of Oncology（2022）

引用 3|浏览2

暂无评分

摘要

In the phase 3 CASPIAN trial, 1L D+EP significantly improved OS vs EP and OS benefit was sustained after >3 years median follow-up (HR 0.71; 95% CI 0.60‒0.86; nominal p=0.0003). Here we assess clinical and molecular characteristics of pts who experienced long-term survival in CASPIAN.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要